EGFR and lung adenocarcinoma: However, it should be remembered that a better understanding of the molecular basis of the ERBB1 gene mutation led to significant success, increasing the overall survival of patients with the above-mentioned mutation, which accounts for approximately 20%–23% of patients with lung adenocarcinoma [109].